Editas Medicine, Inc. (EDIT): Price and Financial Metrics

Editas Medicine, Inc. (EDIT): $5.06

0.43 (-7.83%)

POWR Rating

Component Grades








Add EDIT to Watchlist
Sign Up

Industry: Biotech




#296 of 351

in industry

EDIT Price/Volume Stats

Current price $5.06 52-week high $11.69
Prev. close $5.49 52-week low $4.91
Day low $5.03 Volume 3,328,600
Day high $5.49 Avg. volume 1,875,831
50-day MA $5.66 Dividend yield N/A
200-day MA $7.76 Market Cap 416.12M

EDIT Stock Price Chart Interactive Chart >

Editas Medicine, Inc. (EDIT) Company Bio

Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.

EDIT Latest News Stream

Event/Time News Detail
Loading, please wait...

EDIT Latest Social Stream

Loading social stream, please wait...

View Full EDIT Social Stream

Latest EDIT News From Around the Web

Below are the latest news stories about EDITAS MEDICINE INC that investors may wish to consider to help them evaluate EDIT as an investment opportunity.

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals

Editas isn't out of the woods yet, but it's better off than before.

Yahoo | December 23, 2023

Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 23%

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...

Yahoo | December 15, 2023

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 14, 2023

Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News

bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.

Yahoo | December 14, 2023

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

Yahoo | December 14, 2023

Read More 'EDIT' Stories Here

EDIT Price Returns

1-mo -9.96%
3-mo -34.46%
6-mo -54.04%
1-year -42.63%
3-year -86.01%
5-year -77.99%
YTD -50.05%
2023 14.21%
2022 -66.59%
2021 -62.13%
2020 136.78%
2019 30.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!